Statins inhibit 3-hydroxy-3-methyl-glutaryl coenzyme A (HMGCoA) reductase, which synthesizes mevalonic acid in the isoprenoid pathways. These pathways lead to squalene and subsequently to cholesterol and related products (e.g., steroids, vitamin D, bile salts, lipoproteins) and have major branches producing cell regulatory substances (e.g., farnesyl-and geranylgeranylconjugated proteins) (1, 2) . Although cholesterol reduction in blood has been widely believed to be beneficial (e.g., less available for accumulation by foam cells in atherosclerotic plaques), the ability of cholesterol reduction to mitigate the incidence and severity of cardiovascular diseases has recently been questioned. Like others (3) (4) (5) (6) (7) (8) (9) (10) , we (11) believe that statins and other substances, for example, plant isoprenoids in the diet (12), have beneficial antithrombotic properties arising through the inhibition of an isoprenoid product other than cholesterol.
However, unlike others, we also believe that this isoprenoid product has cell regulatory functions upregulated by thrombin stimulation. Moreover, through such cellular pathways, thrombin should upregulate its own generation, and statins and dietary isoprenoids should induce hypothrombotic states by downregulating thrombin generation ( Fig. 1 ). HYPOTHESIS 1. Antithrombotic properties of statins are independent of their ability to inhibit cholesterol biosynthesis.
2. Statins inhibit HMGCoA reductase, where cholesterol is produced primarily in the liver, and other isoprenoid products made in nonhepatic cells participate in cell signaling transduction pathways (e.g., farnesyl and geranylgeranyl proteins). 3 . Statin antithrombotic effects result from blocking of signal transduction, spanning from activation of protease activated receptor-1 (PAR-1) to protein biosynthesis and expression in thrombin-stimulated events (e.g., upregulation of tissue factor [TF] as well as PAR-1 ). 4 . Upregulated TF activates the TF blood coagulation pathway increasing thrombin generation where thrombin activates PAR-1, completing the cycle, and amplifies thrombin generation. 5 . Chronic low-level thrombin generation induces hyperthrombotic disease-associated conditions (e.g., thrombosis, atherosclerosis, various cancers), and conversely, statins may downregulate chronic thrombin generation and promote hypothrombotic states.
CLINICAL RELEVANCE
Various clinical trials have suggested that statins may reduce cardiovascular disease earlier and to a greater extent than predicted from cholesterol reduction (3) (4) (5) 10) . Besides cholesterol reduction, statins have been shown to decrease biosynthesis of mevalonic acid and its products dolichol and ubiquinone, which have farnesyl and geranylgeranyl diphosphates as intermediates, respectively (13, 14) . Therefore, statins should downregulate farnesyl-and/or geranylgeranyl-conjugated proteins (15, 16) involved in cell signaling (e.g., G-protein a and y subunits, Ras proteins) or perhaps downsize signal transduction by some other mechanism. In addition to statin drugs, various natural products (e.g., isoprenoids from fruits, vegetables, cereal grains, plant oils, flavorings, wines, and secondarily from eggs and dairy products) inhibit mevalonic acid synthesis. Such dietary isoprenoids may further explain low incidences of cancers and cardiovascular diseases in geographical regions of high consumption (12). Within the past three years, Ferro et al. (17) reported that simvastatin at 20 mg daily for 2 months reduced total cholesterol by 24%, prothrombin fragment 1.2 (or FIG. 1. A schematic drawing depicting a mechanism where statins may downregulate thrombin generation at the cellular level. This depiction is in part derived from a similar diagram showing how thrombin might upregulate certain cancers (39) . Since its publication, Bar-Shavit and collaborators (40) have found that PAR-1 is preferentially expressed in highly metastatic human breast carcinoma and that PAR-1 is transiently expressed in invading cytotrophoblasts, implicating PAR-1 in tumor progression as well as embryonic development. The thrombin form with high fibrinogen clotting activity is a-thrombin (20) (21) (22) and can be converted by pPA to 13-and y-thrombins with essentially no clotting activities (37) , allowing for overt (with clotting) and cryptic (without clotting) involvement of thrombin (39) . Dash-dot lines indicate other possible regulatory mechanisms for tPA and pPA (33, 34) . Symbols not defined in the text are: Fll for coagulation factor II or prothrombin; FVIII for factor VIII; FXIII for factor XIII; FVa, FVlla, FXa, and FXllla for respective activated factors; vWF for von Willebrand factor, and PL for phospholipids. (Figure courtesy of John W. Fenton II). thrombin generation) by 35%, and monocyte TF activity and antigen by 61% and 68%, respectively. Recently, Romano et al. (18) reported that fluvastatin at 80 mg daily for 3 months reduced plasma selectin levels of ICAM-1 and P-selectin by 14% and 31%, respectively. They also found levels of thromboxane B2 decreased by 27%, while the potential for nitric oxide generation was increased by 98%, suggesting that fluvastatin mitigated platelet activation and improved endothelial cell functions. Also, Szczeklik et al. (19) have just published that simvastatin will inhibit thrombin generation without additive effects of aspirin in patients with marked hypercholesterolemia.
PROPOSED MECHANISMS
Thrombin has several important functions in thrombosis, thrombotic diseases, preventing hemorrhaging, and developmental and wound healing processes (20) . Traditionally, the primary function of thrombin has been considered to be the conversion of fibrinogen into clot-table fibrin, but the more important functions of thrombin appear to be at the cellular level, such as thrombin stimulation of platelets, leukocytes, endothelial cells, and smooth muscle cells. In the truest sense, thrombin is a multifunctional cell stimulatory proteinase. Whereas severe suppression of thrombin generation potentially causes hemophilic-like conditions, mild retardation should promote antithrombotic benefits, particularly for patients with thrombotic tendencies. Thrombin generation is regulated by a variety of mechanisms (e.g., dilution from blood flow, consumption by inhibitors, partitioning by fibrin, amplification from thrombin induced mechanisms) including those at the cellular level (20) (21) (22) .
Thrombin stimulates many cell types (e.g., endothelial and smooth muscle cells) via PAR-1, which other proteases may stimulate also (23) and upregulates the availability of a variety of proteins, including selectins (24), TF (25) , and PAR-1 (26) . Selectin expression denotes cellular activation and contributes to cellular adhesion.
Upregulation of TF promotes thrombin generation through the TF blood coagulation pathway (extrinsic pathway) and upregulation of PAR-1 (26) further amplifies thrombin generation. In addition, thrombin upregulates components of the fibrinolytic system, tissue plasminogen activator (tPA), urokinase plasminogen activator (~,PA), and plasminogen activator inhibitor-1 (PAI-1) (27) . To account for these facts and the preceding clinical observations, we propose that statins downregulate one or more isoprenoid-dependent steps in cell signaling following thrombin activation of PAR-1 (Fig. 1 ). Such a dependent step would most likely involve a farnesyland/or geranylgeranyl-conjugated protein (e.g., Gprotein a and y subunits, Ras proteins), although other less likely mechanisms could occur. Thrombin stimulates Ras proteins in platelets (28) and induces PAR-1 gene expression in endothelial cells via activation of a Gi protein-linked Ras/mitogen-activated protein kinase pathway (26) . This implies the involvement of an isoprenoiddependent step in G-protein coupling and/or a Ras protein, which is downregulated by statins via HMGCoA reductase in affected cells.
Isoprenoid pathways may predominately lead to different products in nonhepatic cells than cholesterol as in hepatic cells. If HMGCoA reductases are true isozymes in different cell types, then differential branch-point gating of isoprenoid pathways could arise through developmental processes and may explain differing products or pleiotropic effects (6) . Protein prenylation occurs by covalent coupling of farnesyl and geranylgeranyl chains to carboxyl terminal-free cysteines of recipient proteins (29) . Such proteins become membrane associated and may function in ordering these proteins for efficiently conducting tasks, such as signal transduction. How spe-cific functions are prioritized under limiting conditions remains to be determined. However, pathways with several prenylated proteins should be more sensitive to HMGCoA reductase inhibition than those with fewer dependent and more stable constituents. Furthermore, HMGCoA reductase occurs in the third step of the isoprenoid pathways (1, 2) allowing it to be perhaps the least efficient step and making it an ideal target for pharmaceutical intervention.
TESTING THE HYPOTHESIS AND FUTURE DIRECTIONS
By taking into consideration the preceding clinical and other evidence, we have proposed the most likely mechanisms for the induction of antithrombotic effects of statin drugs and dietary isoprenoids (see Hypothesis; Fig. 1 ). First, most of the evidence points to the inhibition of HMGCoA reductase by statins and dietary plant isoprenoids, although the latter could also affect subsequent enzymes in isoprenoid synthesis (12) . Second, proposed mechanisms involve thrombin-induced signal transduction via prenylated proteins. Thus, farnesyl and geranylgeranyl transferase inhibitors should block thrombinstimulated responses, which are dependent on prenylated proteins. Third, temporal and quantitative relations are predicted for thrombin-stimulated proteins (e.g., TF, PAR-1, tPA, RPA) if they are controlled by the same or similar regulatory mechanisms. Of these proteins, RPA may not belong to the same group, since it is not stimulated in tissue culture by factor Xa, whereas TF, PAI-1, and tPA are (30) . Likewise, PAI-1 is reported to be increased or decreased in patients by statins, while tPA was unchanged or increased (31, 32) . However, recent tissue culture and animal experiments provide strong evidence for statins downregulating PAI-1 and upregulating tPA (33) and J.LPA (34) . Since PAI-1 is a major inhibitor of tPA and J.LP A (Fig. 1 ), depression of this inhibitor by statins may further contribute to increased fibrinolytic activity. Also, statins may stimulate the synthesis of other proteins, such as enzymes in the nitroxide pathway (18, 35) Other evidence implies that lovastatin inhibits thrombin signaling through PAR-I in tissue culture (36) .
Fourth, a-thrombin with high fibrinogen clotting activity (20) (21) (22) may be converted by p,PA to thrombin forms, which essentially lack clotting (37) and are presumably r3-and y-thrombins (20) (21) (22) . Recently, y-thrombin has been reported to activate protease activated receptor-4 (PAR-4) (38); therefore, selective inhibitors of PAR-1, PAR-4, etc. should be useful probes for assessing receptor-mediated mechanisms, as well as novel pharmaceutical approaches.
The common usage of PAR-1, perhaps PAR-4, and other receptors merits further investigations in search of anticancer and other antineioplastic agents (39, 40) . Stat-ins reduce atherosclerotic development and platelet responses in animal models (41 ) , whereas hirudin (a highly specific and potent inhibitor of a-thrombin) (20) reduces restenosis in other animal models (42) . These findings implicate thrombin as a mediating agent in atherosclerosis and other forms of cardiovascular disease. Other studies have shown statins to have antithrombotic-related effects in noncholesterolemic animal tissues (33, 35) , in agreement with clinical trials demonstrating an independence between cholesterol reduction and antithrombotic benefits (43) . After all, 80% of the individuals who develop coronary disease have cholesterol levels within the normal range (7) .
In our scheme (Fig. 1 ), cholesterol reduction is an indirect indicator of the antithrombotic properties of HMGCoA reductase inhibitors, and clearly, better diagnostic methods are needed for monitoring their effectiveness (e.g., TF and PAR-1 assays). Increased administration of statin drugs (natural and synthetic) and consumption of various plant isoprenoids from food sources may significantly, if not markedly increase life expectancies. Statin administration sufficiently before scheduled surgery may reduce possible thrombotic and other complications. Nutraceutical HMGCoA reductase inhibitors derived from natural and/or genetically engineered sources (44) may have profound benefits in preventing and treating of cardiovascular and neoplastic diseases.
